RILYZ

Neutral

B. Riley reiterates buy on Zymeworks stock after Theravance acquisition

B. Riley has reiterated its "buy" rating and $40 price target for Zymeworks Inc. following the company's announcement to acquire Theravance Biopharma ...

Investing.com 6 hours ago 0

Neutral

NioCorp launched as Buy at B. Riley, saying stock trades at sizable discount (NB:NASDAQ)

B. Riley has initiated coverage on NioCorp Developments (NB) with a Buy rating and a $12 price target. The firm believes NioCorp's stock is trading at...

Seeking Alpha 2 weeks ago 0